Pharmacogenetics of alcohol and alcohol dependence treatment

Current Pharmaceutical Design

Volumn 16, Issue 19, 2010, Pages 2141-2148

  Kranzler, Henry R ^a   Edenberg, Howard J ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA2; ALCOHOL; ASPARAGINE; ASPARTIC ACID; DOPAMINE 4 RECEPTOR; GLUTAMIC ACID; KAINIC ACID RECEPTOR; MU OPIATE RECEPTOR; NALTREXONE; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; OLANZAPINE; TOPIRAMATE; 4 AMINOBUTYRIC ACID A RECEPTOR; DRD4 PROTEIN, HUMAN; GABRA2 PROTEIN, HUMAN; GLUK1 KAINATE RECEPTOR; OPRM1 PROTEIN, HUMAN;

ALCOHOLISM; DOPAMINERGIC SYSTEM; GABAERGIC SYSTEM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; NEUROTRANSMISSION; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VARIABLE NUMBER OF TANDEM REPEAT; ANIMAL; DRINKING BEHAVIOR; GENETIC POLYMORPHISM; GENETICS; PREVENTION AND CONTROL;

ALCOHOL DRINKING; ALCOHOLISM; ANIMALS; GENETIC VARIATION; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D4; RECEPTORS, GABA-A; RECEPTORS, KAINIC ACID; RECEPTORS, OPIOID, MU;

EID: 77955633815     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791516387     Document Type: Review

References (103)

1. Edenberg HJ, Kranzler HR. The contribution of genetics to addiction therapy approaches. Pharmacol Ther 2005; 108(1): 86-93.
2. Gelernter J, Kranzler HR. Genetics of alcohol dependence. Hum Genet 2009; 126(1): 91-9.
3. Kieffer BL. Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell Mol Neurobiol 1995; 15(6): 615-35.
4. Mollereau C, Parmentier M, Mailleux P, et al. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 1994; 341(1): 33-8.
5. Reinscheid RK, Nothacker HP, Bourson A, et al. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 1995; 270(5237): 792-4.
6. Meunier JC, Mollereau C, Toll L, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995; 377(6549): 532-5.
7. Mansour A, Watson SJ. Anatomical distribution of opioid receptors in mammalians: an overview. Handb Exp Pharmacol 1993; 104: 79- 105.
8. Goldstein A, Naidu A. Multiple opioid receptors: ligand selectivity profiles and binding site signatures. Mol Pharmacol 1989; 36(2): 265-72.
9. Yu L. The mu opioid receptor: from molecular cloning to functional studies. Addict Biol 1996; 1(1): 19-30.
10. Spanagel R, Herz A, Shippenberg TS. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA 1992; 89(6): 2046-50.
11. Matthes HW, Maldonado R, Simonin F, et al. Loss of morphineinduced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996; 383(6603): 819- 23.
12. Sora I, Takahashi N, Funada M, et al. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 1997; 94(4): 1544-9.
13. Gianoulakis C. Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr Top Med Chem 2009; 9(11): 999-1015.
14. Roberts AJ, McDonald JS, Heyser CJ, et al. mu-Opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther 2000; 293(3): 1002-8.
15. Froehlich JC, Zweifel M, Harts J, et al. Importance of delta opioid receptors in maintaining high alcohol drinking. Psychopharmacology (Berl) 1991; 103(4): 467-72.
16. Krishnan-Sarin S, Jing SL, Kurtz DL, et al. The delta opioid receptor antagonist naltrindole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference. Psychopharmacology (Berl) 1995; 120(2): 177-85.
17. Roberts AJ, Gold LH, Polis I, et al. Increased ethanol selfadministration in delta-opioid receptor knockout mice. Alcohol Clin Exp Res 2001; 25(9): 1249-56.
18. Kovacs KM, Szakall I, O'Brien D, et al. Decreased oral selfadministration of alcohol in kappa-opioid receptor knock-out mice. Alcohol Clin Exp Res 2005; 29(5): 730-8.
19. Edenberg HJ, Wang J, Tian H, et al. A regulatory variation in OPRK1, the gene encoding the kappa-opioid receptor, is associated with alcohol dependence. Hum Mol Genet 2008; 17(12): 1783-9.
20. Xuei X, Dick D, Flury-Wetherill L, et al. Association of the kappaopioid system with alcohol dependence. Mol Psychiatry 2006; 11(11): 1016-24.
21. Zhang H, Kranzler HR, Yang BZ, et al. The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol Psychiatry 2008; 13(5): 531-43.
22. Traynor JR, Elliott J. delta-Opioid receptor subtypes and cross-talk with mu-receptors. Trends Pharmacol Sci 1993; 14(3): 84-6.
23. Spanagel R, Herz A, Shippenberg TS. The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem 1990; 55(5): 1734-40.
24. Bergen AW, Kokoszka J, Peterson R, et al. Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry 1997; 2(6): 490-4.
25. Arias A, Feinn R, Kranzler HR. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend 2006; 83(3): 262-8.
26. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 1998; 95(16): 9608-13.
27. Zhang Y, Wang D, Johnson AD, et al. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 2005; 280(38): 32618-24.
28. Ray LA, Hutchison KE. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 2004; 28(12): 1789-95.
29. van den Wildenberg E, Wiers RW, Dessers J, et al. A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin Exp Res 2007; 31(1): 1-10.
30. Wand GS, McCaul M, Yang X, et al. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 2002; 26(1): 106-14.
31. Hernandez-Avila CA, Wand G, Luo X, et al. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet B Neuropsychiatr Genet 2003; 118B(1): 60-5.
32. Hernandez-Avila CA, Covault J, Wand G, et al. Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1) on HPA-axis activation. Pharmacogenet Genomics 2007; 17(12): 1031-8.
33. Zhang H, Luo X, Kranzler HR, et al. Association between two muopioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum Mol Genet 2006; 15(6): 807-19.
34. McGeary JE, Monti PM, Rohsenow DJ, et al. Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcohol Clin Exp Res 2006; 30(8): 1288-96.
35. Ray LA, Hutchison KE. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo- controlled study. Arch Gen Psychiatry 2007; 64(9): 1069-77.
36. Bouza C, Angeles M, Munoz A, et al. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004; 99(7): 811-28.
37. Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2005; 8(2): 267-80.
38. Monterosso JR, Flannery BA, Pettinati HM, et al. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 2001; 10(3): 258-68.
39. Rubio G, Ponce G, Rodriguez-Jimenez R, et al. Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone? Alcohol Alcohol 2005; 40(3): 227- 33.
40. Krishnan-Sarin S, Krystal JH, Shi J, et al. Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking. Biol Psychiatry 2007; 62(6): 694-7.
41. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28(8): 1546-52.
42. Gelernter J, Gueorguieva R, Kranzler HR, et al. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res 2007; 31(4): 555-63.
43. Krystal JH, Cramer JA, Krol WF, et al. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001; 345(24): 1734-9.
44. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295(17): 2003-17.
45. Kim SG, Kim CM, Choi SW, et al. A μ opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl) 2009; 201(4): 611-8.
46. Mitchell JM, Fields HL, White RL, et al. The Asp40 mu-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers. J Clin Psychopharmacol 2007; 27(1): 112-5.
47. Tidey JW, Monti PM, Rohsenow DJ, et al. Moderators of naltrexone's effects on drinking, urge, and alcohol effects in nontreatment- seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res 2008; 32(1): 58-66.
48. Arias AJ, Armeli S, Gelernter J, et al. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res 2008; 32(7): 1159-66.
49. Karhuvaara S, Simojoki K, Virta A, et al. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res 2007; 31(7): 1179-87.
50. Knapp CM, Ciraulo DA, Kranzler HR. Neurobiology of alcohol. In Galanter M, Kleber HD (Eds) Textbook of Substance Abuse Treatment, 4th Edition, Washington, DC: American Psychiatric Press, Inc. 2008: pp. 111-127.
51. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988; 85(14): 5274-8.
52. Volkow ND, Wang GJ, Maynard L, et al. Effects of alcohol detoxification on dopamine D2 receptors in alcoholics: a preliminary study. Psychiatry Res 2002; 116(3): 163-72.
53. Heinz A, Siessmeier T, Wrase J, et al. Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry 2004; 161(10): 1783- 9.
54. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 2004; 23(6): 540-5.
55. Yang BZ, Kranzler HR, Zhao H, et al. Association of haplotypic variants in DRD2, ANKK1, TTC12 and NCAM1 to alcohol dependence in independent case control and family samples. Hum Mol Genet 2007; 16(23): 2844-53.
56. Dick DM, Wang JC, Plunkett J, et al. Family-based association analyses of alcohol dependence phenotypes across DRD2 and neighboring gene ANKK1. Alcohol Clin Exp Res 2007; 31(10): 1645-53.
57. Lawford BR, Young RM, Rowell JA, et al. Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele. Nat Med 1995; 1(4): 337-41.
58. Ray LA, Bryan A, Mackillop J, et al. The dopamine D Receptor (DRD4) gene exon III polymorphism, problematic alcohol use and novelty seeking: direct and mediated genetic effects. Addict Biol 2009; 14(2): 238-44.
59. Hutchison KE, McGeary J, Smolen A, et al. The DRD4 VNTR polymorphism moderates craving after alcohol consumption. Health Psychol 2002; 21(2): 139-46.
60. Hutchison KE, Wooden A, Swift RM, et al. Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology 2003; 28(10): 1882-8.
61. Hutchison KE, Ray L, Sandman E, et al. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology 2006; 31(6): 1310-7.
62. Mackillop J, Menges DP, McGeary JE, et al. Effects of craving and DRD4 VNTR genotype on the relative value of alcohol: an initial human laboratory study. Behav Brain Funct 2007; 3: 11.
63. van den Wildenberg E, Janssen RG, Hutchison KE, et al. Polymorphisms of the dopamine D4 receptor gene (DRD4 VNTR) and cannabinoid CB1 receptor gene (CNR1) are not strongly related to cuereactivity after alcohol exposure. Addict Biol 2007; 12(2): 210-20.
64. Feldstein Ewing SW, LaChance HA, Bryan A, et al. Do genetic and individual risk factors moderate the efficacy of motivational enhancement therapy? Drinking outcomes with an emerging adult sample. Addict Biol 2009; 14(3): 356-65.
65. Porjesz B, Almasy L, Edenberg HJ, et al. Linkage disequilibrium between the beta frequency of the human EEG and a GABAA receptor gene locus. Proc Natl Acad Sci USA 2002; 99(6): 3729-33.
66. Edenberg HJ, Dick DM, Xuei X, et al. Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations. Am J Hum Genet 2004; 74(4): 705-14.
67. Enoch MA, Hodgkinson CA, Yuan Q, et al. GABRG1 and GABRA2 as independent predictors for alcoholism in two populations. Neuropsychopharmacology 2009; 34(5): 1245-54.
68. Covault J, Gelernter J, Hesselbrock V, et al. Allelic and haplotypic association of GABRA2 with alcohol dependence. Am J Med Genet B Neuropsychiatr Genet 2004; 129(1): 104-9.
69. Lappalainen J, Krupitsky E, Remizov M, et al. Association between alcoholism and gamma-amino butyric acid alpha2 receptor subtype in a Russian population. Alcohol Clin Exp Res 2005; 29(4): 493-8.
70. Fehr C, Sander T, Tadic A, et al. Confirmation of association of the GABRA2 gene with alcohol dependence by subtype-specific analysis. Psychiatr Genet 2006; 16(1): 9-17.
71. Lind PA, Macgregor S, Agrawal A, et al. The role of GABRA2 in alcohol dependence, smoking, and illicit drug use in an Australian population sample. Alcohol Clin Exp Res 2008; 32(10): 1721-31.
72. Enoch MA, Schwartz L, Albaugh B, et al. Dimensional anxiety mediates linkage of GABRA2 haplotypes with alcoholism. Am J Med Genet B Neuropsychiatr Genet 2006; 141B(6): 599-607.
73. Soyka M, Preuss UW, Hesselbrock V, et al. GABA-A2 receptor subunit gene (GABRA2) polymorphisms and risk for alcohol dependence. J Psychiatr Res 2008; 42(3): 184-91.
74. Drgon T, D'Addario C, Uhl GR. Linkage disequilibrium, haplotype and association studies of a chromosome 4 GABA receptor gene cluster: candidate gene variants for addictions. Am J Med Genet B Neuropsychiatr Genet 2006; 141B(8): 854-60.
75. Matthews AG, Hoffman EK, Zezza N, et al. The role of the GABRA2 polymorphism in multiplex alcohol dependence families with minimal comorbidity: within-family association and linkage analyses. J Stud Alcohol Drugs 2007; 68(5): 625-33.
76. Covault J, Gelernter J, Jensen K, et al. Markers in the 5'-region of GABRG1 associate to alcohol dependence and are in linkage disequilibrium with markers in the adjacent GABRA2 gene. Neuropsychopharmacology 2008; 33(4): 837-48.
77. Ray LA, Hutchison KE. Associations among GABRG1, level of response to alcohol, and drinking behaviors. Alcohol Clin Exp Res 2009; 33(8): 1382-90.
78. Pierucci-Lagha A, Covault J, Feinn R, et al. GABRA2 alleles moderate the subjective effects of alcohol, which are attenuated by finasteride. Neuropsychopharmacology 2005; 30(6): 1193-203.
79. Haughey HM, Ray LA, Finan P, et al. Human gamma-aminobutyric acid A receptor alpha2 gene moderates the acute effects of alcohol and brain mRNA expression. Genes Brain Behav 2008; 7(4): 447- 54.
80. Bauer LO, Covault J, Harel O, et al. Variation in GABRA2 predicts drinking behavior in project MATCH subjects. Alcohol Clin Exp Res 2007; 31(11): 1780-7.
81. Dick DM, Plunkett J, Wetherill LF, et al. Association between GABRA1 and drinking behaviors in the collaborative study on the genetics of alcoholism sample. Alcohol Clin Exp Res 2006; 30(7): 1101-10.
82. Dick DM, Edenberg H.J, Xuei X, et al. Association of GABRG3 with alcohol dependence. Alcohol Clin Exp Res 2004; 28(1): 4-9.
83. Xuei X, Flury-Wetherill L, Dick D, et al. GABRR1 and GABRR2, encoding the GABA-A receptor subunits rho1 and rho2, are associated with alcohol dependence. Am J Med Genet B Neuropsychiatr Genet 2009;
84. Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 2009; 10(8): 561-72.
85. Edwards G, Gross MM. Alcohol dependence: provisional description of a clinical syndrome. Br Med J 1976; 1(6017): 1058-61.
86. Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 2008; 75(1): 218-65.
87. Schumann G, Johann M, Frank J, et al. Systematic analysis of glutamatergic neurotransmission genes in alcohol dependence and adolescent risky drinking behavior. Arch Gen Psychiatry 2008; 65(7): 826-38.
88. Carta M Ariwodola OJ, Weiner JL, et al. Alcohol potently inhibits the kainate receptor-dependent excitatory drive of hippocampal interneurons. Proc Natl Acad Sci USA 2003; 100(11): 6813-8.
89. Kranzler HR, Gage A. Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials. Am J Addict 2008; 17(1): 70-6.
90. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361(9370): 1677-85.
91. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298(14): 1641-51.
92. Pinheiro P, Mulle C. Kainate receptors. Cell Tissue Res 2006; 326(2): 457-82.
93. Gryder DS, Rogawski MA. Selective antagonism of GluR5 kainatereceptor- mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci 2003; 23(18): 7069-74.
94. Kaminski RM, Banerjee M, Rogawski MA. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 2004; 46(8): 1097-104.
95. Kranzler HR, Gelernter J, Anton RF, et al. Association of markers in the 3' region of the GluR5 kainate receptor subunit gene to alcohol dependence. Alcohol Clin Exp Res 2009; 33(5): 925-30.
96. Preuss UW, Zill P, Koller G, et al. Ionotropic glutamate receptor gene GRIK3 SER310ALA functional polymorphism is related to delirium tremens in alcoholics. Pharmacogenomics J 2006; 6(1): 34-41.
97. Samochowiec J, Grzywacz A, Kucharska-Mazur J, et al. Familybased and case-control association studies of glutamate receptor GRIK3 Ser310Ala polymorphism in Polish patients and families with alcohol dependence. Neurosci Lett 2006; 396(2): 159-62.
98. Uhl GR, Liu QR, Drgon T, et al. Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry 2008; 65(6): 683-93.
99. Miranda R, Jr., MacKillop J, Monti PM, et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res 2008; 32(3): 489-97.
100. Ray LA, Miranda R, Jr., MacKillop J, et al. A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol 2009; 17(2): 122-9.
101. Berrocoso E, Sanchez-Blazquez P, Garzon J, et al. Opiates as antidepressants. Curr Pharm Des 2009; 15(14): 1612-22.
102. Christmas D, Hood S, Nutt D. Potential novel anxiolytic drugs. Curr Pharm Des 2008; 14(33): 3534-46.
103. Wang LL, Yang AK, He SM, et al. Identification of Molecular Targets Associated With Ethanol Toxicity and Implications in Drug Development. Curr Pharm Des 2010; 16(11): 1315-55.